Uniqure NV (NASDAQ:QURE) – SunTrust Banks lifted their Q2 2020 EPS estimates for Uniqure in a note issued to investors on Wednesday, June 24th. SunTrust Banks analyst R. Karnauskas now anticipates that the biotechnology company will post earnings per share of ($0.97) for the quarter, up from their prior forecast of ($0.98). SunTrust Banks also issued estimates for Uniqure’s Q3 2020 earnings at ($1.02) EPS, Q4 2020 earnings at $0.10 EPS, FY2020 earnings at ($2.50) EPS, FY2021 earnings at $1.31 EPS, FY2022 earnings at ($1.96) EPS, FY2023 earnings at ($1.45) EPS and FY2024 earnings at ($0.89) EPS.
A number of other research firms also recently issued reports on QURE. Stifel Nicolaus dropped their price objective on shares of Uniqure from $86.00 to $78.00 and set a “buy” rating on the stock in a research note on Thursday, June 25th. They noted that the move was a valuation call. Mizuho reiterated a “neutral” rating and set a $61.00 price objective (down from $90.00) on shares of Uniqure in a research note on Thursday, June 25th. ValuEngine downgraded shares of Uniqure from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, April 14th. Wells Fargo & Co downgraded shares of Uniqure from an “overweight” rating to an “equal weight” rating and lowered their target price for the company from $90.00 to $56.00 in a research note on Thursday, June 25th. Finally, Chardan Capital lowered their target price on shares of Uniqure from $105.00 to $80.00 and set a “buy” rating for the company in a research note on Thursday, June 25th. Five equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $74.00.
Uniqure (NASDAQ:QURE) last released its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.84) by $0.21. Uniqure had a negative net margin of 1,991.17% and a negative return on equity of 45.23%. The firm had revenue of $0.10 million for the quarter, compared to the consensus estimate of $1.76 million.
Several institutional investors have recently modified their holdings of QURE. Janus Henderson Group PLC purchased a new position in shares of Uniqure during the first quarter worth $34,493,000. Point72 Asset Management L.P. raised its holdings in shares of Uniqure by 468.9% during the fourth quarter. Point72 Asset Management L.P. now owns 570,180 shares of the biotechnology company’s stock worth $40,859,000 after purchasing an additional 469,948 shares during the last quarter. Norges Bank purchased a new position in shares of Uniqure during the fourth quarter worth $27,094,000. UBS Asset Management Americas Inc. raised its holdings in shares of Uniqure by 148.7% during the fourth quarter. UBS Asset Management Americas Inc. now owns 575,826 shares of the biotechnology company’s stock worth $41,264,000 after purchasing an additional 344,276 shares during the last quarter. Finally, Senator Investment Group LP purchased a new position in shares of Uniqure during the fourth quarter worth $23,289,000. 78.65% of the stock is owned by hedge funds and other institutional investors.
In other Uniqure news, insider Robert Gut sold 26,875 shares of the firm’s stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $70.00, for a total value of $1,881,250.00. Also, CEO Matthew C. Kapusta sold 9,376 shares of the firm’s stock in a transaction on Wednesday, April 22nd. The stock was sold at an average price of $56.87, for a total transaction of $533,213.12. Following the completion of the transaction, the chief executive officer now directly owns 327,918 shares of the company’s stock, valued at approximately $18,648,696.66. The disclosure for this sale can be found here. In the last ninety days, insiders sold 46,002 shares of company stock valued at $3,044,829. Corporate insiders own 2.66% of the company’s stock.
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.
Further Reading: Limitations of the P/E Growth ratio
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.